This document serves as a formal correction to the 2017 study published in Oncogene, which investigated the mechanisms of chemoresistance in esophageal squamous cell carcinoma (ESCC). The original research identified a critical pathway where Interleukin-6 (IL6) secreted by cancer-associated fibroblasts (CAFs) triggers resistance to chemotherapy through the CXCR7 signaling axis.
The Nature of the Correction
The authors issued this correction to address inadvertent errors in data presentation, specifically regarding the use of representative images in multi-panel figures. In high-impact oncology research, visual data such as flow cytometry plots and immunohistochemistry (IHC) slides must uniquely represent the experimental conditions described.
The correction identifies two primary instances of image duplication:
- Apoptosis Assays: An inadvertent duplication of a flow cytometry plot occurred between Figure 4c and Figure 2b during figure assembly.
- Control Data: Figure 1d and Figure 6b originally shared control data from the same experiment. To ensure clarity and independence of results, the authors replaced the images in Figure 6b with data from a different patient sample.
Key Results and Visual Updates
The primary visual update concerns the flow cytometry data measuring apoptosis in TE7 cell lines. The corrected Figure 4c provides the unique quadrant for the shCXCR7+IL6 experimental group, which is essential for demonstrating how silencing CXCR7 affects cell death even in the presence of IL6.
In the updated Figure 4c, the shCXCR7+IL6 group shows an apoptosis rate (Annexin-V positive) of approximately 61.5% (combining the 41.9% and 19.6% quadrants). This data supports the original finding that CXCR7 knockdown sensitizes cells to apoptosis, counteracting the protective effects of IL6.
Additionally, Figure 6b was updated with new IHC images for the CN and CT panels. This ensures that the representative histology for these patient samples is distinct and unique to the figure, maintaining the integrity of the correlation between protein expression and clinical outcomes.
Scientific Integrity and Conclusions
Crucially, the authors emphasize that these visual corrections do not alter the quantitative results or the fundamental scientific conclusions of the study. The IL6-CXCR7 axis remains a validated driver of chemoresistance in ESCC. This correction serves to maintain the accuracy of the scientific record and ensure that future researchers are working from a perfectly accurate visual dataset. The authors have apologized for the oversight, noting that the underlying raw data and statistical analyses remain sound.
Summary updated